Drugs that contain Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir
1. List of Viekira Pak (copackaged) drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8501238 | ABBVIE INC | Anti-infective agents and uses thereof |
Dec, 2028
(5 years from now) | |
| US8188104 | ABBVIE INC | Anti-infective agents and uses thereof |
May, 2029
(6 years from now) | |
| US8642538 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(6 years from now) | |
| US8420596 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(8 years from now) | |
| US8691938 | ABBVIE INC | Anti-viral compounds |
Apr, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8268349 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(1 year, 6 months from now) | |
| US8399015 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(1 year, 6 months from now) | |
| US9139536 | ABBVIE INC | Anti-infective agents and uses thereof |
Nov, 2028
(5 years from now) | |
| US9006387 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(7 years from now) | |
| US9044480 | ABBVIE INC | Compositions and methods for treating HCV |
Apr, 2031
(8 years from now) | |
| US8686026 | ABBVIE INC | Solid compositions |
Jun, 2031
(8 years from now) | |
| US8685984 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US8466159 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US8680106 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US8492386 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US9629841 | ABBVIE INC | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(10 years from now) | |
| US10201542 | ABBVIE INC | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(10 years from now) | |
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin.; Use of dasabuvir to inhibit viral replication for the treatment of hcv infection.
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic